Pfizer stock sits in an awkward middle ground for valuation right now, with a roughly 21% share price decline over five years set against checks that suggest the current price looks neither clearly cheap nor clearly expensive.

• Over the past five years, Pfizer shares have declined about 21%, which means long term holders have not been rewarded for their patience so far.
• Regulatory progress in areas like oncology and weight loss can support higher earnings expectations, while ongoing pricing pressures and political scrutiny of clinical work in China may limit how much of that optimism investors are willing to pay for.
• On Simply Wall St's broader valuation checks, Pfizer scores 4 out of 6. This points to a mixed picture rather than a clear bargain or obvious overvaluation.

The issue now is whether Pfizer's current valuation gives you enough compensation for the recent share price record and the balance of its opportunities and risks.

Does Pfizer Look Fairly Valued on Earnings?

The P/E ratio suits Pfizer because earnings are still the main anchor for how the market prices a large, diversified pharmaceutical group. Pfizer currently trades on a P/E of about 18.7x, compared with a pharmaceuticals industry average of 14.7x and a peer average near 26.3x. That leaves the stock priced above the broader sector, but below many large-cap peers that investors also treat as core holdings.

Simply Wall St's fair P/E ratio for Pfizer is 19.6x, which is very close to where the stock sits now, suggesting the market is largely in line with what this framework implies given its mix of earnings, size and risk. Despite recent headlines around oncology approvals and weight loss efforts shaping sentiment, the current multiple does not show a clear discount or a glaring premium versus this tailored fair value yardstick.

On the P/E measure, Pfizer stock currently looks roughly fairly valued rather than clearly cheap or expensive.

The Pfizer Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Pfizer pick up where the valuation puzzle leaves off by spelling out what would need to happen to Pfizer's growth, margins and earnings for the stock to be worth materially more or less than today's price, and they sit on the company's Community page. Rather than focusing on a single multiple or model output, each narrative lays out the assumptions behind its fair value view so you can compare those expectations with Pfizer's actual results over time.

Community views on Pfizer sit far apart, with one camp focused on pipeline upside and the other on policy and patent risks.

Bull case: 16% undervalued

"Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages…"

Bear case: roughly fairly valued

"The company's revenue trajectory is threatened by the accelerating loss of market exclusivity on major drugs such as Eliquis and Ibrance, both of which are expected to lose patent protection by 2027, resulting in a dramatic revenue cliff as generic and biosimilar competitors erode market share and profitability…"

Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!

The Bottom Line

Pfizer now trades on a P/E that leaves the stock looking about right rather than clearly undervalued or overvalued, so the easy valuation argument is no longer on the table. With broader checks also pointing to a mixed picture, the key question is whether future earnings can justify even a modest premium to the wider pharmaceuticals group. For many investors, the real swing factor is whether the late stage pipeline and new launches can offset patent expiries and policy pressures strongly enough to keep that multiple intact or support a re rating over time.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.